Announcement • Jun 23
Centene Corporation Appoints Lauren M. Tyler to the Board of Directors, Effective June 19, 2026, and to Audit Committee and Compensation and Talent Committee, Effective July 1, 2026 Centene Corporation announced the appointment of Lauren M. Tyler to its Board of Directors, effective June 19, 2026. Ms. Tyler will serve on the Audit Committee and Compensation and Talent Committee, effective as of July 1, 2026. Ms. Tyler brings more than 30 years of leadership experience across investment banking, private equity, corporate audit, investor relations, and human capital strategy. Ms. Tyler spent over two decades at JPMorgan Chase & Co., where she held senior roles including Executive Vice President and Global Head of Human Resources for Asset and Wealth Management, Global Firmwide Chief Auditor, and Global Head of Investor Relations. Earlier in her career, she held roles at TSG Capital Partners, Allen & Company, and Morgan Stanley. She currently serves on the boards of Cencora Inc., and Guardian Life. She previously served on the board of Alleghany Corporation until its acquisition in 2022. Ms. Tyler holds an MBA from Harvard Business School and a BA from Yale University. Recent Insider Transactions • Jun 14
Director recently sold €4.5m worth of stock On the 10th of June, Kenneth Burdick sold around 80k shares on-market at roughly €55.87 per share. This transaction amounted to 22% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of €6.0m more than they bought in the last 12 months. Board Change • May 20
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 6 experienced directors. 2 highly experienced directors. Independent Director Ken Tanji was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 30
Centene Corporation Updates Earnings Guidance for the Year 2026 Centene Corporation updated earnings guidance for the year 2026. For the year, the Company increased 2026 GAAP Diluted EPS Guidance to greater than $2.37. The company expects total revenue from $187.5 billion to $191.5 billion. Announcement • Apr 07
Centene Corporation Announces New Executive Appointments Centene Corporation announced the creation of two new executive leadership positions, which will report to Chief Executive Officer Sarah London. Centene has hired Daniel Finke as Group President, Markets and Commercial, and appointed Michael Carson to Group President, Medicare and Specialty. Finke, a seasoned healthcare executive with more than two decades of experience leading and scaling complex health plan organizations across government and commercial markets, will oversee the Medicaid and Commercial segments. He joins Centene from Convey Health Solutions, where he served as Chief Executive Officer. Prior to joining Convey, he was Executive Vice President of CVS Health and President of Aetna, leading strategy and operations spanning Medicare, Medicaid, and Commercial insurance businesses. As Group President, Medicare and Specialty, Michael Carson will have expanded oversight of Centene's Medicare Advantage, Medicare Part D, Duals, and Specialty businesses. Carson's experience spans nearly three decades of healthcare leadership. Prior to joining Centene in January 2024 as CEO of its Medicare business, Wellcare, Carson served as Chief Executive Officer for Bright Healthcare and Harvard Pilgrim Health Care, as well as CareAbout, a multi-specialty, value-based care delivery organization. Announcement • Mar 27
Centene Corporation, Annual General Meeting, May 12, 2026 Centene Corporation, Annual General Meeting, May 12, 2026. Location: centene plaza, 7700 forsyth boulevard, st. louis, missouri 63105, centene auditorium, United States Announcement • Mar 25
Centene Corporation Announces Executive Changes, Effective March 18, 2026 Centene Corporation announced that effective March 18, 2026, the Board of Directors appointed Theodore Pienkos, age 44, a registered CPA, to serve as the Company's Corporate Controller and Chief Accounting Officer. Mr. Pienkos previously has served as the Company's Deputy Corporate Controller since August 2024. Prior to that, he served as Vice President of Finance & Accounting from August 2017 to August 2024, and he has held other accounting roles of increasing importance with Centene since March 2011. Before joining Centene, Mr. Pienkos served as an auditor for KPMG LLP from August 2004 to March 2011. He holds a BA and MA in Accounting from the University of Northern Iowa. Centene Corporation also announced that Kate Casso, who has been with the Company for over two decades and served as the Company's prior Corporate Controller and Chief Accounting Officer since April 2021, has been appointed Senior Vice President, Finance Operations and Innovation, effective as of March 18, 2026. In this role, Ms. Casso will devote part of her time to innovation, both enterprise-wide and within Finance, while continuing to lead Data Analytics, Medical Economics, Payment Integrity, Finance Shared Services, Financial Planning and Analysis, and other various Finance teams. Announcement • Feb 07
An undisclosed buyer signed a definitive agreement to acquire an unknown minority stake in Magellan Health, Inc. from Centene Corporation (NYSE:CNC). An undisclosed buyer signed a definitive agreement to acquire an unknown minority stake in Magellan Health, Inc. from Centene Corporation (NYSE:CNC) in December, 2025. Announcement • Feb 06
Centene Corporation Provides Earnings Guidance for the Fiscal Year Ending December 31, 2026 Centene Corporation provided earnings guidance for the fiscal year ending December 31, 2026. The Company expects its 2026 GAAP diluted EPS guidance of greater than $1.98 and Total revenues of $186.5 billion to $190.5 billion. Announcement • Nov 07
Centene Corporation's Ambetter from Arizona Complete Health Offers Health Insurance in Arizona in 2026 Centene Corporation's Ambetter from Arizona Complete Health will offer a variety of affordable health insurance plans to Arizonans in nine counties for plan year 2026. The open enrollment period for the Health Insurance Marketplace runs from Nov. 1, 2025, through Jan. 15, 2026. Enroll by Dec. 15, 2025, for coverage starting Jan. 1, 2026. Ambetter Health Solutions: Ambetter Health Solutions, Centene Corporation's off-exchange marketplace business offerings, delivers individual health insurance plans that are compatible with Individual Coverage Health Reimbursement Arrangements (ICHRAs). While not an ICHRA itself, Ambetter Health Solutions supports employers who choose to adopt this reimbursement model by providing employees with access to affordable, customizable and dependable coverage options. Available in select states, including Arizona, these plans empower individuals to choose the coverage that best fits their needs, helping employers control costs while offering greater choice and flexibility to their workforce. Ambetter Perks: Ambetter from Arizona Complete Health offers additional services to support health and financial well-being through the Ambetter Perks program for members in Arizona. This program gives members access to discounts on a variety of products and services, including wellness activities, financial tools, memberships, out-of-pocket prescription costs and over-the-counter (OTC) health items. It also includes services that promote healthy lifestyles and address social factors that impact health. The Ambetter Perks program is open to all members. Convenient Online Enrollment: Through the Ambetter from Arizona Complete Health website, people can browse and compare coverage options, determine their eligibility for financial subsidies and directly enroll in coverage -- all in one place. The platform is accessible through mobile devices, so people can enroll using smartphones. If a person is unable to complete enrollment all at once, the system will save progress and provide reminders to finish enrollment. My Health Pays: Members have access to the My Health Pays®? program, where they can earn points for practicing healthy eating habits, staying active and leading a healthy lifestyle. Through the program, members can complete health-related activities and challenges to earn up to $500 in rewards in 2026. These rewards can be used for health-related expenses such as copays and deductibles (pharmacy copays are excluded). My Health Pays also allows members to set and reach health goals at their own pace by providing seasonal suggestions for activities and guidance to help stay on track. Virtual 24/7 Care: Virtual 24/7 Care offers members a licensed provider via telehealth for members to access care for illnesses such as flu, skin conditions, ear infections, fever and respiratory infections -- all from the comfort of their home. Announcement • Oct 31
Centene Corporation Reports Impairment Charges for the Third Quarter 2025 Centene Corporation reported impairment charges for the third quarter 2025. For the quarter, the company reported non-cash goodwill impairment charge of $6.7 billion. Announcement • Oct 29
Centene Corporation Updates Earnings Guidance for the Full Year 2025 Centene Corporation updated earnings guidance for the full year 2025. The Company is updating its full year 2025 GAAP forecast to a diluted loss per share not to exceed $12.85. Announcement • Sep 29
Centene Corporation to Report Q3, 2025 Results on Oct 29, 2025 Centene Corporation announced that they will report Q3, 2025 results at 6:00 AM, US Eastern Standard Time on Oct 29, 2025 Announcement • Aug 07
Centene Corporation Stock Drop Triggers Securities Fraud Class Action Bleichmar Fonti & Auld LLP announced that a lawsuit has been filed against Centene Corporation and certain of the Company’s senior executives for potential violations of the federal securities laws. Investors have until September 8, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities. The case is pending in the U.S. District Court for the Southern District of New York and is captioned: Lunstrum v. Centene Corporation, et al., No. 25-cv-05659. Centene is a healthcare company that focuses on providing services to consumers enrolled in government-sponsored healthcare programs like Medicaid and Medicare, as well as those that purchase insurance under the Affordable Care Act from the Health Insurance Marketplace. On December 12, 2024, Centene announced financial guidance for fiscal year 2025 which the company said reflected “[s]tability in earnings power in the face of unprecedented headwinds.” Next, on February 4, 2025, Centene increased its 2025 guidance due to enrollment “overperformance.” Then, on April 25, 2025, Centene again increased 2025 guidance due to continued strong growth in enrollment and retention, while touting the “progress we are making as an organization while navigating a dynamic policy landscape.” In truth, the majority of the market that Centene serves was experiencing lower than expected enrollment growth and increased morbidity rates, or frequency of disease and illness. On July 1, 2025, Centene abruptly withdrew its previous guidance after reviewing an independent actuarial report from Wakely Consulting Group which showed that overall market growth in 22 of the 29 states Centene serves was lower than expected and that morbidity in those states was significantly higher than expected. On this news, the price of Centene stock fell $22.87 per share, or more than 40%, from $56.65 per share on July 1, 2025 to $33.78 per share on July 2, 2025. Announcement • Jul 02
Centene Corporation to Report Q2, 2025 Results on Jul 25, 2025 Centene Corporation announced that they will report Q2, 2025 results on Jul 25, 2025 Announcement • Apr 25
Centene Corporation Re-Iterates Earnings Guidance for the Full Year 2025 Centene Corporation re-iterated earnings guidance for the full year 2025. For the year, the company expects increasing its 2025 premium and service revenues guidance range by $6.0 billion to a range of $164.0 billion to $166.0 billion to reflect the following expectations: $5.0 billion of additional Marketplace premium revenue due to outperformance in enrollment throughout the first quarter; and outperformance in the Medicare Advantage annual enrollment period resulting in $1.0 billion of additional premium revenue. The Company reiterates its 2025 GAAP diluted EPS guidance floor of greater than $6.1. Announcement • Mar 28
Centene Corporation, Annual General Meeting, May 13, 2025 Centene Corporation, Annual General Meeting, May 13, 2025. Location: centene plaza, 7700 forsyth blvd, missouri 63105, st.louis United States Announcement • Feb 25
Centene Corporation Appoints Kenneth Y. Tanji to Board of Directors and Member of Audit and Compliance Committee Centene Corporation announced the appointment of Kenneth Y. Tanji to the Centene Board of Directors, effective February 20, 2025. Mr. Tanji will serve on the Company's Audit and Compliance Committee. The appointment of Mr. Tanji expands Centene's Board of Directors to 12 members. Mr. Tanji's finance acumen spans more than three decades and includes deep knowledge of capital optimization strategies, strategic acquisitions, JV partnership models and the use of advanced analytics and technologies to scale growth. Mr. Tanji most recently served as Executive Vice President and Chief Financial Officer of Prudential Financial Inc. from 2018 to 2024. From 1988 to 2018, he held numerous leadership roles across Prudential's insurance, health insurance, annuities, and investment management businesses. Mr. Tanji currently serves on the Board of The Public Service Enterprise Group Inc. He is also a Corporate Finance professor at Rutgers University. Announcement • Feb 05
Centene Corporation to Report Q1, 2025 Results on Apr 25, 2025 Centene Corporation announced that they will report Q1, 2025 results at 8:30 AM, Eastern Daylight on Apr 25, 2025 Announcement • Feb 04
Centene Corporation Reiterates Earnings Guidance for the Year 2025 Centene Corporation reiterated earnings guidance for the year 2025. The company reiterated its 2025 GAAP diluted EPS guidance floor of greater than $6.19 and its 2025 adjusted diluted EPS guidance floor of greater than $7.25. Announcement • Jan 09
Centene Corporation Names Alan Silver as the President of Its Ambetter Health Solutions Business Centene Corporation announced that Alan Silver has joined the organization as the President of its Ambetter Health Solutions business, which focuses on ICHRA (Individual Coverage Health Reimbursement Arrangements). This newly created role reflects Centene's belief that consumers increasingly will seek health insurance that offers transparency, customization, choice and convenience. ICHRA plans allow employees to shop on the individual Marketplace and choose the insurance plan that works best for them, using a tax-free stipend from their employer. Silver will bring more than two decades of leadership experience in benefits administration and actuarial consulting to the role, including a proven record of driving growth, developing client-focused benefit solutions and pioneering exchange-based healthcare strategies. Most recently, Silver led retiree medical and ICHRA initiatives at Willis Towers Watson. His expertise uniquely positions him to lead Ambetter's efforts in expanding and enhancing ICHRA offerings to meet and drive evolving market needs. Announcement • Dec 16
Centene Corporation to Report Fiscal Year 2024 Results on Feb 04, 2025 Centene Corporation announced that they will report fiscal year 2024 results at 6:00 AM, US Eastern Standard Time on Feb 04, 2025 Announcement • Dec 13
Centene Corporation Provides Earnings Guidance for the Fiscal Year 2025 Centene Corporation provided earnings guidance for the fiscal year 2025. The Company expects its 2025 GAAP diluted EPS guidance of greater than$6.19 and Total revenues of $166.5 billion to $169.5 billion. Announcement • Oct 26
Centene Corporation Provides Earnings Guidance for the Year 2024 Centene Corporation provided earnings guidance for the year 2024. The Company is updating its 2024 GAAP diluted EPS guidance floor to greater than $5.92. Total revenues to be in the range of $159 billion to $161 billion. Reported Earnings • Oct 25
Third quarter 2024 earnings released: EPS: US$1.37 (vs US$0.87 in 3Q 2023) Third quarter 2024 results: EPS: US$1.37 (up from US$0.87 in 3Q 2023). Revenue: US$42.0b (up 19% from 3Q 2023). Net income: US$713.0m (up 52% from 3Q 2023). Profit margin: 1.7% (up from 1.3% in 3Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 3.2% p.a. on average during the next 3 years, compared to a 3.5% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 37% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Oct 22
Investor sentiment deteriorates as stock falls 15% After last week's 15% share price decline to €56.43, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 14x in the Healthcare industry in Germany. Total loss to shareholders of 4.4% over the past three years. Announcement • Oct 08
Centene Corporation to Report Q3, 2024 Results on Oct 25, 2024 Centene Corporation announced that they will report Q3, 2024 results at 6:00 AM, US Eastern Standard Time on Oct 25, 2024 Announcement • Oct 04
Ambetter Health of Delaware Offers Health Insurance in Delaware in 2025 Ambetter Health of Delaware, a product offered by a Centene Corporation company, which provides insurance to under-insured and uninsured populations through the federal Health Insurance Marketplace®, will offer Delawareans a variety of affordable health insurance plans in plan year 2025. Open enrollment for the Health Insurance Marketplace for Delaware runs from Nov. 1, 2024, through Dec. 15, 2024, for coverage starting Jan. 1, 2025. Enroll by Dec. 15, 2024, for coverage starting Jan. 1, 2025. Ambetter Health of Delaware offers its members access to quality care, convenient services and valuable rewards. The 2025 benefits and offerings include: Affordable and Reliable Coverage: Ambetter Health of Delaware provides coverage for all essential health benefits, including preventive and wellness services, maternity and newborn care, pediatric services, mental health services, hospitalizations and prescription drug coverage. Some plans also include dental and vision coverage. Virtual 24/7 Care: Virtual 24/7 Care offers members an Ambetter-designated licensed provider via telehealth for members to access care for illnesses such as flu, skin conditions, ear infections, fever and respiratory infections – all from the comfort of their own home. Convenient Online Enrollment: Through the Ambetter Health of Delaware website, people can browse and compare coverage options, determine their eligibility for financial subsidies and directly enroll in coverage – all in one place. The platform is accessible through mobile devices, so people can enroll using smartphones. If a person is unable to complete enrollment all at once, the system will save progress and provide reminders to finish enrollment. My Health Pays: Members have access to the My Health Pays program, where they can earn points for practicing healthy eating habits, staying active and leading a healthy lifestyle. Through the program, members can complete health-related activities and challenges and can earn up to $500 in rewards in 2025. These rewards can be used for health-related expenses such as premiums, copays and deductibles (pharmacy copays are excluded). My Health Pays® also allows members to set and reach health goals at their own pace by providing seasonal suggestions for activities and guidance to help stay on track. Premier Network: Beginning Jan. 1, 2025, the Ambetter Health Bronze|Silver|Gold network will become known as the Premier Network. Members can continue to rely on the same provider network with the doctors and hospitals they know and trust. Ambetter Health of Delawarewill be offered in New Castle, Kent and Sussex counties in 2025. Announcement • Aug 16
Centene Corporation Announces the Election of Thomas R. Greco to Board of Directors Centene Corporation announced that it has appointed Thomas R. Greco to the Centene Board of Directors, effective August 9, 2024. Mr. Greco's term will run through the Company's 2025 annual meeting of stockholders. The appointment of Mr. Greco expands Centene's Board of Directors to 11 members. Mr. Greco is a seasoned operator and executive who brings more than four decades of public company leadership and expertise to Centene. Over the course of his career, he has implemented growth strategies and fostered talent development and diversity for consumer-focused companies. He most recently served as President and Chief Executive Officer (CEO) of Advance Auto Parts Inc., a Raleigh-based automotive parts retailer, from 2016 to 2023. Prior to his tenure at Advance Auto Parts, Mr. Greco spent three decades in roles of increasing responsibility at PepsiCo before becoming CEO of Frito-Lay North America in 2011. Mr. Greco currently serves on the boards of Tapestry Inc., a publicly traded, multinational fashion company, the Sabra Dipping Company LLC, a joint venture between PepsiCo and the Strauss Group, and the American Heart Association. A longtime advocate for cardiovascular health, Mr. Greco has been actively involved in several initiatives aimed at enhancing the nutritional profile of consumer products throughout his career. Valuation Update With 7 Day Price Move • Aug 02
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to €70.93, the stock trades at a forward P/E ratio of 13x. Average forward P/E is 14x in the Healthcare industry in Germany. Total returns to shareholders of 22% over the past three years. Reported Earnings • Jul 28
Second quarter 2024 earnings released: EPS: US$2.16 (vs US$1.93 in 2Q 2023) Second quarter 2024 results: EPS: US$2.16 (up from US$1.93 in 2Q 2023). Revenue: US$36.4b (up 3.6% from 2Q 2023). Net income: US$1.15b (up 8.3% from 2Q 2023). Profit margin: 3.1% (up from 3.0% in 2Q 2023). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, compared to a 3.7% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has only increased by 3% per year, which means it is significantly lagging earnings growth. Announcement • Jul 04
Centene Corporation to Report Q2, 2024 Results on Jul 26, 2024 Centene Corporation announced that they will report Q2, 2024 results at 6:00 AM, US Eastern Standard Time on Jul 26, 2024 Announcement • Apr 27
Centene Corporation Updates Earnings Guidance for the Year 2024 Centene Corporation updated earnings guidance for the year 2024. For the year, the Company is updating its 2024 diluted EPS guidance floor to greater than $5.94. Total revenue is expected to be in range of $147.5 Billion to $150.5 Billion. Reported Earnings • Apr 26
First quarter 2024 earnings released: EPS: US$2.17 (vs US$2.05 in 1Q 2023) First quarter 2024 results: EPS: US$2.17 (up from US$2.05 in 1Q 2023). Revenue: US$40.4b (up 14% from 1Q 2023). Net income: US$1.16b (up 2.9% from 1Q 2023). Profit margin: 2.9% (down from 3.2% in 1Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 4.5% p.a. on average during the next 3 years, compared to a 4.3% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 29% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Announcement • Mar 30
Centene Corporation, Annual General Meeting, May 14, 2024 Centene Corporation, Annual General Meeting, May 14, 2024, at 10:00 Central Standard Time. Location: Centene Plaza 7700 Forsyth Boulevard St. Louis, Missouri 63105 Centene Auditorium Missouri United States Agenda: To consider elect ten directors to hold office until the 2025 Annual Meeting of Stockholders or until their successors are duly elected and qualified; to discuss cast a non-binding advisory vote on the compensation of the Company's Named Executive Officers; to ratify the appointment of KPMG LLP as independent registered public accounting firm for the fiscal year ending December 31, 2024; and to discuss Stockholder proposal. Announcement • Mar 08
Centene Corporation to Report Q1, 2024 Results on Apr 26, 2024 Centene Corporation announced that they will report Q1, 2024 results at 6:00 AM, US Eastern Standard Time on Apr 26, 2024 Reported Earnings • Feb 22
Full year 2023 earnings released: EPS: US$4.97 (vs US$2.09 in FY 2022) Full year 2023 results: EPS: US$4.97 (up from US$2.09 in FY 2022). Revenue: US$141.3b (up 3.9% from FY 2022). Net income: US$2.70b (up 125% from FY 2022). Profit margin: 1.9% (up from 0.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.0% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 15% per year, which means it is significantly lagging earnings growth. Reported Earnings • Feb 07
Full year 2023 earnings released: EPS: US$4.97 (vs US$2.09 in FY 2022) Full year 2023 results: EPS: US$4.97 (up from US$2.09 in FY 2022). Revenue: US$141.5b (up 4.0% from FY 2022). Net income: US$2.70b (up 125% from FY 2022). Profit margin: 1.9% (up from 0.9% in FY 2022). The increase in margin was driven by higher revenue. Revenue is forecast to grow 4.8% p.a. on average during the next 3 years, while revenues in the Healthcare industry in Germany are expected to remain flat. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Announcement • Feb 06
Centene Corporation Increases Premium and Service Revenues Guidance for the Fiscal Year 2024 Centene Corporation increased premium and service revenues guidance for the fiscal year 2024. for the year, the company increased premium and service revenues guidance range by $2.5 billion to a range of $134.5 billion to $137.5 billion to reflect additional Commercial premium revenue from a stronger than expected Marketplace open enrollment. Announcement • Jan 23
Centene Corporation Announces Appointment of Michael A. Carson as President and Chief Executive Officer of Its Medicare Business Centene Corporation announced two appointments. Michael A. Carson joins Centene as President and Chief Executive Officer of its Medicare business, Wellcare. Mr. Carson will be responsible for Medicare business performance, strategy and growth and will report to Centene President Ken Fasola. Carson succeeds Richard Fisher, who has been appointed to the Operations leadership team under Centene Chief Operating Officer Susan Smith. Mr. Fisher will have responsibility for key financial and operational processes across Shared Services, as well as lead enterprise development, management and optimization of Centene's key vendor partnerships. Mr. Carson brings nearly three decades of seasoned leadership, operational and industry expertise in both the payer and provider space with a deep focus on and expertise in serving Medicare and dual-eligible populations. As the CEO of value-based primary and multi-specialty care start-up CareAbout, he led a fully delegated, risk-bearing Medicare and dual-eligible-focused care delivery organization. Mr. Carson also served as the CEO of Bright Health Plan and as the President and CEO of Harvard Pilgrim Health Care. He led the formation and rebuilding of Medicare businesses at both Amerigroup and Anthem, as well as served in transformative leadership roles at ConcertoHealth and other Blue Cross Blue Shield plans. Mr. Carson started his career in the United States Air Force, where he served for almost a decade before transitioning to corporate roles. Mr. Carson earned a Bachelor of Science in Business Administration from the University of Phoenix. He serves as Non-Executive Board Chair of HYKE, and as an Advisory Board Member of both Foodsmart and OneHealth. Announcement • Jan 13
Pure Health LLC completed the acquisition of Circle Health Group Limited from Centene Corporation (NYSE:CNC). Pure Health LLC agreed to acquire Circle Health Group Limited from Centene Corporation (NYSE:CNC) for an enterprise value of approximately $1.2 billion on August 28, 2023. The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the first quarter of 2024. Barclays is serving as financial advisor to Centene, and Dickson Minto is serving as its legal counsel. BofA Securities, Inc. acted as financial advisor to Pure Health LLC. Braeden Donnelly, Simon Rahimzada, Michel Sheng and Joshua Cole, Neil Cunninghame, Simon Swann, Mark Spinney, Bradley Rice, Rhiannon Webster, Sunny Kumar, Eleanor Reeves, Henry Moss, John Gordo and Briony Holcombe of Ashurst LLP and Ashurst, Dubai acted as Legal advisor to Pure Health LLC
Pure Health LLC completed the acquisition of Circle Health Group Limited from Centene Corporation (NYSE:CNC) on January 12, 2024. Announcement • Dec 13
Centene Corporation to Report Fiscal Year 2023 Results on Feb 06, 2024 Centene Corporation announced that they will report fiscal year 2023 results at 6:00 AM, US Eastern Standard Time on Feb 06, 2024 Announcement • Dec 12
Centene Corporation Provides Earnings Guidance for the Fiscal Year 2024 Centene Corporation provided earnings guidance for the fiscal year 2024. For the year, the company expected total revenues of $142.5 billion to $145.5 billion. GAAP diluted earnings per share (EPS) of greater than $5.61. Announcement • Nov 17
Centene Corporation Announces the Appointment of Susan Smith as Chief Operating Officer, Effective January 1, 2024 Centene Corporation announced the appointment of Susan Smith as its Chief Operating Officer (COO), effective January 1, 2024. As COO, Ms. Smith will report to Centene President Ken Fasola and will be responsible for core business operations, population health, the enterprise transformation office, provider experience and quality. She has worked at Centene since June 2023.Ms. Smith brings nearly two decades of expertise in the payer space, having spent 19 years at Humana. She most recently served as SVP of Clinical, Quality and Enterprise Solutions President, where she had oversight of quality; clinical strategy, analytics and product development; clinical operations; risk adjustment; and experience transformation. Prior to this role, Ms. Smith served as SVP of Clinical Solutions and SVP of Medicare. Among numerous accomplishments during her tenure, she is credited for her work in leading Humana's efforts to improve its Star ratings and member quality; in playing a central role in the design and development of Medicaid operations for Humana; and for her experienced leadership creating sustainable organizations and processes during transformative times. She held other leadership roles, including SVP of Healthcare Quality Reporting and Improvement, and Vice President of Risk Adjustment, among others. Ms. Smith started her career at Colgate-Palmolive. Ms. Smith earned a Bachelor of Science in Chemical Engineering and a Master of Engineering in Chemical Engineering -- both from the University of Louisville Speed Scientific School. Announcement • Oct 25
Centene Corporation Names Wade Rakes as Chief Growth Officer Centene Corporation announced it has named Wade Rakes its Chief Growth Officer. Mr. Rakes, who currently serves as Plan President and Chief Executive Officer of Centene's Georgia-based subsidiary, Peach State Health Plan ("Peach State"), will leverage his extensive Medicaid, business development and health plan leadership experience to support and advance the Company's uniquely local business model in collaboration with Centene's health plans and lines of business. Drawing on Centene's mission and expertise, he will deepen the Company's relationships with members, communities and partners; drive intentional expansion across existing products; and identify growth opportunities in new products and markets. Mr. Rakes will serve both roles until a new Peach State Plan President and CEO is appointed and will continue to serve as Chair of the Board of Peach State. Mr. Rakes brings more than two decades of business and healthcare industry experience. At Peach State, he led one of the state's largest insurance plans, providing more than 1.3 million Georgians with access to high-quality Medicaid, Medicare Advantage and Marketplace plans. Prior to this role, Mr. Rakes served as Centene's Regional Vice President, Business Development, Growth and Expansion, with responsibility for driving more than $5 billion in annualized new business opportunities as well as overseeing the startup of health plans in both Pennsylvania and California. He also played a leading role in the business development and integration work of several key Centene acquisitions, including Fidelis Care, Health Net and Wellcare. Mr. Rakes previously served as the Company's first Chief Diversity and Inclusion Officer. Before joining Centene in 2010, he served as Senior Advisor to the Governor of Ohio and Director of Public Liaison for the state. Early in his career he held roles of increasing responsibility for Showtime Networks. Mr. Rakes earned a Bachelor of Arts in Economics from Princeton University and an MBA from the University of Michigan. He is a member of the Board of Directors of the High Museum in Atlanta; the Metro Atlanta Chamber; the LGBTQ+ Victory Fund (Chair); Beyond Differences (Chair); the Board of Advisors of the James A. Baker III Institute at Rice University; and the President's Advisory Council at Princeton University. Reported Earnings • Oct 25
Third quarter 2023 earnings released: EPS: US$0.87 (vs US$1.29 in 3Q 2022) Third quarter 2023 results: EPS: US$0.87 (down from US$1.29 in 3Q 2022). Revenue: US$35.2b (up 2.2% from 3Q 2022). Net income: US$469.0m (down 36% from 3Q 2022). Profit margin: 1.3% (down from 2.1% in 3Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 2.4% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 10% per year whereas the company’s share price has increased by 8% per year. Announcement • Oct 25
Centene Corporation Provides Earnings Guidance for the Full Year 2023 Centene Corporation provided earnings guidance for the full year 2023. For the year, the company updated total revenues to be $149 billion to $151 billion and GAAP diluted EPS at least $4.88. Announcement • Oct 05
Centene Corporation to Report Q3, 2023 Results on Oct 24, 2023 Centene Corporation announced that they will report Q3, 2023 results at 6:00 AM, US Eastern Standard Time on Oct 24, 2023 Announcement • Aug 29
Pure Health LLC agreed to acquire Circle Health Group Limited from Centene Corporation (NYSE:CNC) for an enterprise value of approximately $1.2 billion. Pure Health LLC agreed to acquire Circle Health Group Limited from Centene Corporation (NYSE:CNC) for an enterprise value of approximately $1.2 billion on August 28, 2023. The transaction is subject to customary closing conditions, including regulatory approvals, and is expected to close in the first quarter of 2024. Barclays is serving as financial advisor to Centene, and Dickson Minto is serving as its legal counsel. Reported Earnings • Jul 29
Second quarter 2023 earnings released: EPS: US$1.93 (vs US$0.29 loss in 2Q 2022) Second quarter 2023 results: EPS: US$1.93 (up from US$0.29 loss in 2Q 2022). Revenue: US$35.3b (up 3.7% from 2Q 2022). Net income: US$1.06b (up US$1.23b from 2Q 2022). Profit margin: 3.0% (up from net loss in 2Q 2022). Revenue is forecast to grow 2.0% p.a. on average during the next 3 years, compared to a 3.8% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 3% per year. Announcement • Jul 29
Centene Corporation Provides Earnings Guidance for the Full Year 2023 Centene Corporation provided earnings guidance for the full year 2023. For the year, the company expects total revenues to be $147.3 billion to $149.3 billion and GAAP diluted EPS at least $5.60. Announcement • Jun 28
Centene Corporation to Report Q2, 2023 Results on Jul 28, 2023 Centene Corporation announced that they will report Q2, 2023 results at 6:00 AM, US Eastern Standard Time on Jul 28, 2023 Announcement • Jun 14
New Mountain Capital, L.L.C. acquired Apixio, Inc. from Centene Corporation. New Mountain Capital, L.L.C. agreed to acquire Apixio, Inc. from Centene Corporation (NYSE : CNC) on May 3, 2023. The transaction is subject to customary closing conditions, including regulatory approvals. William Blair acted as financial advisor and Bass, Berry & Sims, PLC acted as legal counsel to Centene. J.P. Morgan Securities LLC acted as financial advisor and Todd B. Kornreich, Garrett Charon, Tim McCrystal, Danna Kivell, Ed McNicholas, Violetta Kokolus, Alyssa Kollmeyer, Jonathan Klarfeld, Arek Maczka and Richard Kidd of Ropes & Gray LLP acted as legal counsel to New Mountain Capital. The Company expects the transaction to be neutral to 2023 adjusted EPS.
New Mountain Capital, L.L.C. completed the acquisition of Apixio, Inc. from Centene Corporation (NYSE : CNC) on June 13, 2023. Announcement • May 25
Centene Corporation Appoints T. Susko as Its Senior Vice President and Chief Communications Officer Centene Corporation announced it has named Shannon T. Susko as its Senior Vice President and Chief Communications Officer. Ms. Susko will be responsible for Centene's communications function, leading the development and execution of all internal and external communications, overseeing corporate reputation and advancing communications strategy in support of the company's business objectives. Ms. Susko is a seasoned communications professional with more than two decades of strategic, corporate and crisis communications experience. She most recently served as Managing Director and Co-Head of Strategic Situations and Investor Relations and Head of Healthcare for Edelman Smithfield – the financial communications boutique within global communications firm Edelman. As a strategic advisor to boards and management teams of public and private companies, Ms. Susko guided communications strategy during both normal course and transformative situations. She previously served as Vice President of Communications at Global Strategy Group, where she advised clients on strategic communications, mergers and acquisitions, shareholder activism, and issues and reputation management. She was the founder of Susko & Co, a consulting firm that advised clients in the healthcare and financial services industries on strategic communications, business development and market strategy. Ms. Susko spent a decade at TriWest Healthcare Alliance, a Department of Defense managed care support contractor responsible for the administration of the military's healthcare program – TRICARE. Ms. Susko earned a Bachelor of Arts from the University of Pennsylvania and an MBA from the W.P. Carey School of Business at Arizona State University. She is a member of the American College of Healthcare Executives and the Healthcare Businesswomen's Association. Announcement • May 23
Centene Corporation Announces Resignation of James E. Murray as Chief Operating Officer Centene Corporation announced on May 19, 2023, James E. Murray, Chief Operating Officer (“COO”), formally notified the Company of his plans to retire in 2024. Over the remainder of the current quarter, Mr. Murray will oversee the transition of his duties as COO to several functional leaders within the Company. For the remainder of his tenure, Mr. Murray will report to Sarah M. London, Centene’s Chief Executive Officer, and focus primarily on advancing the Company’s Medicare strategy. Announcement • May 05
New Mountain Capital, L.L.C. agreed to acquire Apixio, Inc. from Centene Corporation (NYSE : CNC). New Mountain Capital, L.L.C. agreed to acquire Apixio, Inc. from Centene Corporation (NYSE : CNC) on May 3, 2023. The transaction is subject to customary closing conditions, including regulatory approvals. William Blair acted as financial advisor and Bass, Berry & Sims, PLC acted as legal counsel to Centene. J.P. Morgan Securities LLC acted as financial advisor and Todd B. Kornreich, Garrett Charon, Tim McCrystal, Danna Kivell, Ed McNicholas, Violetta Kokolus, Alyssa Kollmeyer, Jonathan Klarfeld, Arek Maczka and Richard Kidd of Ropes & Gray LLP acted as legal counsel to New Mountain Capital. The Company expects the transaction to be neutral to 2023 adjusted EPS. Announcement • May 04
Centene to Divest AI Platform Apixio Centene Corporation (NYSE:CNC) will sell its artificial intelligence-powered healthcare analytics platform Apixio, Inc. to investment firm New Mountain Capital as part of an ongoing portfolio review, the U.S. health insurer said on May 3, 2023. The company, which acquired Apixio in December 2020, did not disclose the terms of the transaction. Apixio compiles and analyzes large volumes of unstructured patient data, including medical charts and physician’s notes, into insights and curated data. “As part of our ongoing portfolio review, it was important for us to find a strategic partner for Apixio with whom the business can continue to grow,” said Centene Chief Executive Office Sarah London said in a statement. Centene said it expects the sale of the platform to be neutral to its adjusted profit for this year. Reported Earnings • Apr 26
First quarter 2023 earnings released: EPS: US$2.05 (vs US$1.46 in 1Q 2022) First quarter 2023 results: EPS: US$2.05 (up from US$1.46 in 1Q 2022). Revenue: US$35.3b (up 3.0% from 1Q 2022). Net income: US$1.13b (up 33% from 1Q 2022). Profit margin: 3.2% (up from 2.5% in 1Q 2022). Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 4.0% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 4% per year whereas the company’s share price has remained flat. Recent Insider Transactions • Mar 19
CEO & Director recently bought €1.8m worth of stock On the 17th of March, Sarah London bought around 30k shares on-market at roughly €58.73 per share. This transaction amounted to 11% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Sarah's only on-market trade for the last 12 months. Recent Insider Transactions • Feb 10
Independent Director recently bought €469k worth of stock On the 8th of February, Theodore Samuels bought around 7k shares on-market at roughly €67.00 per share. This transaction amounted to 50% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought €2.6m more in shares than they have sold in the last 12 months. Announcement • Feb 08
Centene Corporation Provides Earnings Guidance for the Full Year 2023 Centene Corporation provided earnings guidance for the full year 2023. The company's new 2023 premium and service revenues guidance range is $131.5 billion to $133.5 billion. Reported Earnings • Feb 08
Full year 2022 earnings released: EPS: US$2.09 (vs US$2.31 in FY 2021) Full year 2022 results: EPS: US$2.09 (down from US$2.31 in FY 2021). Revenue: US$145.8b (up 23% from FY 2021). Net income: US$1.20b (down 11% from FY 2021). Profit margin: 0.8% (down from 1.1% in FY 2021). Revenue is forecast to grow 1.2% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Healthcare industry in Germany. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Announcement • Dec 17
Centene Corporation to Report Fiscal Year 2022 Results on Feb 07, 2023 Centene Corporation announced that they will report fiscal year 2022 results at 6:00 AM, US Eastern Standard Time on Feb 07, 2023 Board Change • Nov 16
High number of new directors There are 7 new directors who have joined the board in the last 3 years. Independent Director Chris Coughlin was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Jul 27
Second quarter 2022 earnings released: US$0.29 loss per share (vs US$0.92 loss in 2Q 2021) Second quarter 2022 results: US$0.29 loss per share (up from US$0.92 loss in 2Q 2021). Revenue: US$36.0b (up 16% from 2Q 2021). Net loss: US$172.0m (loss narrowed 68% from 2Q 2021). Over the next year, revenue is forecast to grow 9.2%, compared to a 4.0% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 9% per year but the company’s share price has increased by 23% per year, which means it is well ahead of earnings. Recent Insider Transactions • May 04
Independent Director recently bought €482k worth of stock On the 28th of April, Theodore Samuels bought around 6k shares on-market at roughly €76.92 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months. Board Change • Apr 27
High number of new directors There are 8 new directors who have joined the board in the last 3 years. Independent Director Chris Coughlin was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Feb 09
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Full year 2021 results: EPS: US$2.31 (down from US$3.17 in FY 2020). Revenue: US$126.8b (up 22% from FY 2020). Net income: US$1.35b (down 26% from FY 2020). Profit margin: 1.1% (down from 1.7% in FY 2020). Revenue was in line with analyst estimates. Over the next year, revenue is forecast to grow 7.1%, compared to a 3.8% growth forecast for the industry in Germany. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has increased by 8% per year, which means it is well ahead of earnings. 